Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stella Petroni is active.

Publication


Featured researches published by Stella Petroni.


British Journal of Cancer | 2000

Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients

A. Paradiso; Giovanni Simone; Stella Petroni; Bernardo Amadeo Leone; Carlos Vallejo; J. Lacava; Alberto Romero; M. Machiavelli; M De Lena; C J Allegra; Patrick G. Johnston

The purpose of this work was to analyse the ability of p53 and thymidilate synthase (TS) primary tumour expression to retrospectively predict clinical response to chemotherapy and long-term prognosis in patients with advanced colorectal cancers homogeneously treated by methotrexate (MTX)-modulated–5-fluorouracil (5-FU-FA). A total of 108 advanced colorectal cancer patients entered the present retrospective study. Immunohistochemical p53 (pAb 1801 mAb) and TS (TS106 mAb) expression on formalin-fixed paraffin-embedded primary tumour specimens was related to probability of clinical response to chemotherapy, time to progression and overall survival. p53 was expressed in 53/108 (49%) tumours, while 54/108 (50%) showed TS immunostaining. No relationship was demonstrated between p53 positivity and clinical response to chemotherapy (objective response (OR): 20% vs 23%, in p53+ and p53– cases respectively) or overall survival. Percent of OR was significantly higher in TS-negative with respect to TS-positive tumours (30% vs 15% respectively; P< 0.04); simultaneous analysis of TS and p53 indicated 7% OR for p53-positive/TS-positive tumours vs 46% for p53-positive/TS-negative tumours (P< 0.03). Logistic regression analysis confirmed a significant association between TS tumour status and clinical response to chemotherapy (hazard ratio (HR): 2.91; 95% confidence interval (CI) 8.34–1.01; two-sided P< 0.05). A multivariate analysis of overall survival showed that only a small number of metastatic sites was statistically relevant (HR 1.89; 95% CI 2.85–1.26; two-sided P< 0.03). Our study suggests that immunohistochemical expression of p53 and TS could assist the clinician in predicting response of colorectal cancer patients to modulated MTX-5-FU therapy.


Oncology | 1988

Correlation between ERICA and DCC Assay in Hormone Receptor Assessment of Human Breast Cancer

M. De Lena; Marzullo F; Giovanni Simone; Labriola A; Stefania Tommasi; Stella Petroni; A. Paradiso

To study the basic relationships between estrogen receptor immunocytochemical assay (ERICA) and dextran-coated charcoal (DCC) techniques, 116 women affected by breast cancer were admitted to the study from June 1985. In 56% of cases the tumor sample came from patients with operable disease and in 44% from patients with advanced inoperable disease. We found an overall agreement of 80% between the two methods characterized by a high sensitivity (95%) and a low specificity of ERICA versus DCC. ER/ICA negative results were found in 20 out of 78 ER/DCC positive cases; on the contrary, discordant results were found in only 3 out of 38 cases described by DCC as ER negative. 29 patients with advanced disease and ER/DCC positive tumors were considered for clinical analysis and reliability of each hormone receptor assay. A clinical response was reached in 69% of ER/DCC positive patients and on 64% of ER/ICA positive ones (16/25). However, it must be noted that 4/29 cases described as negative by ERICA were clinically responsive to hormone therapy.


Cancer Genetics and Cytogenetics | 2008

Genetic heterogeneity by comparative genomic hybridization in BRCAx breast cancers

Anita Mangia; Patrizia Chiarappa; Stefania Tommasi; Annalisa Chiriatti; Stella Petroni; Francesco Schittulli; Angelo Paradiso

The chromosomal changes in eight familial BRCAx breast cancers (i.e., negative for BRCA1 or BRCA2) were analyzed by comparative genomic hybridization (CGH) to investigate intratumor heterogeneity. This was the first step in a study of most frequent chromosomal aberrations in BRCAx familial breast cancers. Laser microdissection analysis of paraffin tissue samples was followed by whole-genome amplification. CGH was performed on DNA isolated from two to three different cell groups per case to detect any cytogenetic aberrations in important clones that might have been missed when analyzing DNA extracted from large numbers of cells. The results were compared, to evaluate the influence of tumor heterogeneity on CGH, and the heterogeneity was confirmed comparing CGH with fluorescence in situ hybridization results. Different chromosomal aberrations were detected between adjacent clones within the same section, which highlights the utility of microdissection in addressing the problem of heterogeneity in whole-genome studies. Some chromosomal regions were more frequently altered in the eight BRCAx tumors; loss of 2q, 3p, 3q, 8p, 9p, and 15q and gains of 1p, 4p, 4q, 5p, 6q, 12q, and 19p were the most common. Further studies focusing on specific genes and sequences with more sensitive approaches, such as array-CGH, are warranted to confirm these findings.


Archives of Pathology & Laboratory Medicine | 2012

Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?

Stella Petroni; Teresa Addati; Eliseo Mattioli; Maria Angela Caponio; Carmela Quero; Vincenza Rubini; Francesco Giotta; Giovanni Simone

CONTEXT Chromosome 17 polysomy has been identified in 5% to 50% of invasive breast cancers; even though a relationship with human epidermal growth factor receptor 2 (HER2/ neu ) status has been reported, other studies have shown that coincident centromere 17 (Cep17) amplification may be the cause of an overestimation of chromosome 17 polysomy in fluorescence in situ hybridization (FISH) testing. OBJECTIVE To evaluate polysomy/amplification of Cep17 in invasive breast cancer with relation to proliferative activity (Ki-67), estrogen receptor, progesterone receptor, and HER2/ neu status, in an attempt to identify a subgroup of patients with a worse prognosis. DESIGN A total of 647 cases of invasive ductal breast cancer were collected and subjected to FISH analysis for HER2/neu gene and centromere 17 alteration, HercepTest for HER2/ neu protein expression, and routine immunohistochemistry for Ki-67 and hormone receptor status. RESULTS Copy number gain of Cep17 was observed in 27.3% of cases. Within this group, HER2/neu gene amplification was detected in 14.1% of cases, whereas HER2/ neu expression was scored 3+ in 20.1% of cases; about half of the HER2/ neu overexpressing cases (9.8%) did not show amplification by FISH. Moreover, 69% of polysomic cases showed high Ki-67 index. CONCLUSIONS (1) Centromere 17-altered cases are frequently HER2/ neu overexpressing but not amplified, resulting in HercepTest/FISH disagreement; (2) HER2/neu amplification is seen at a higher incidence in cases without Cep17 copy number alterations, which are therefore not necessarily due to chromosome 17 disorder; (3) proliferation index is significantly higher in aneusomic tumors. These data suggest that the presence of Cep17 alterations could identify a subset of breast cancers with more aggressive biological and clinical behavior, which may show nonresponsiveness to conventional therapy independently of HER2/neu amplification status.


Cancer Biomarkers | 2014

P16INK4a protein expression in endocervical, endometrial and metastatic adenocarcinomas of extra-uterine origin: Diagnostic and clinical considerations

Maria Angela Caponio; Teresa Addati; Ondina Popescu; Stella Petroni; Vincenza Rubini; Marilena Centrone; Giuseppe Trojano; Giovanni Simone

Determining the primary site of uterine adenocarcinoma (ADC) may be problematic, especially with small specimens. This is particularly important in light of the increase of endocervical and endometrial adenocarcinoma and the decrease in incidence of squamous cell carcinoma. P16(INK4a) , a member of the INK4 family of cell cycle regulatory proteins, plays a critical role. It functions as a negative regulator of cell cycle progression and differentiation by controlling the activity of the tumor-suppressor protein retinoblastoma (pRb), which regulates the cell cycle. Its expression is variable according to the tumoral histotype and in metastasis. The aim of this study was to investigate P16(INK4a) expression in endocervical, endometrial, and metastatic ADCs of extra-uterine origin. Fifty gynaecological biopsies (cervix or endometrium) comprised the study for P16(INK4a) determination. Cases were classified as (1) diffuse positive (P), in intense nuclear immunostaining and/or cytoplasmic in > 30% of neoplastic cells; (2) focal positive (FP), in intense immunostaining in 10% to 30% in isolated cells or small groups; and (3) negative (N), in absence of immunostaining or weak, sporadic immunostaining in < 10% of neoplastic cells. Included in the study were the following: 6 endocervical ADCs, 11 endometrioid-type endometrial ADCs, 5 endometrial serous papillary ADCs, 7 ovarian ADCs, 4 large intestine ADCs, 1 breast ADC, 12 not-otherwise-specified (NOS) ADCs, and 4 endocervical biopsy without atypia (as control). Diffuse, strong positivity with P16(INK4a) suggests an endocervical rather than an endometrial or metastatic ADC. In fact, a P16(INK4a) positive immunostaining pattern was prevalent in endocervical (83%) and serous papillary ADCs of endometrial or ovarian origin, whereas endometrioid ADCs such as metastatic non-ovarian lesions generally presented only focal or negative immunostaining. 10/12 cases of ADC-NOS were reclassified using P16(INK4a) immunostaining: 2 as endocervical ADCs (2 P), 4 as endometrioid-type endometrial ADCs (2 FP, 2 N), 3 as endometrial serous papillary ADCs (3 FP), and 1 as ovarian serous papillary ADC (1 FP).


Translational lung cancer research | 2016

Metachronous primary uterine cancer surgically resected during Crizotinib treatment in a ALK-rearranged advanced lung adenocarcinoma

Annamaria Catino; Andrea Misino; Anna Scattone; Lucia Caldarola; Stella Petroni; Antonio Logroscino; Elisabetta Sara Montagna; Gabriella Serio; Giovanni Simone; Domenico Galetta

Rearrangements of the anaplastic lymphoma kinase (ALK) gene are present in 3% to 7% of non-small-cell lung cancers (NSCLCs). Patients harboring ALK rearrangements show very favourable outcomes if treated with targeted agents, among which crizotinib is the first and best studied. Crizotinib, an oral small-molecule tyrosine kinase inhibitor of ALK, MET, and ROS1 kinases, is a very active and well tolerated drug. Nevertheless, the optimal therapy management with this new drug is still partially unknown, especially with regard to the safety of combined treatments. Recently, the integration of locoregional treatments has been proposed as a feasible multimodality strategy in selected patients with good clinical conditions and slow-growing or oligoprogressive disease. In this report, a case of advanced lung adenocarcinoma, progressed after first line chemotherapy and re-biopsied detecting ALK rearrangement, is described. During crizotinib treatment the primary lung tumor showed an excellent regression; meanwhile a major surgery for a metachronous uterine cancer was safely and successfully carried out.


Journal of Clinical Oncology | 2011

Chromosome (Ch17) disorder and Ki67expression: Negative prognostic factors in invasive breast cancer.

Stella Petroni; T. Addati; F. Giotta; M. Centrone; E. Mattioli; M. Caponio; C. Quero; Vincenza Rubini; G. Giannone; A. Millaku; Giovanni Simone

e21073 Background: Ch17 polysomy has been identified in 20-40% of invasive breast cancer, probably related to HER-2 protein expression, but other studies failed to confirm this relation, demonstrating that its a rare event. The aim of this study was to evaluate Cep17 alterations in invasive breast cancer related to Ki67, hormonal receptor status and HER-2 expression Methods: 647 cases of ductal invasive breast cancer diagnosed between 2007 and 2009, were collected. Immunostaining of estrogen and progesteron receptors (61%), and Ki67 was performed on 629 cases; receptor positive status and high Ki67 index has been detected in 61% and 60% of tumours, respectively. HER-2 protein overexpression was evidenced on 107/608 samples (17.6%). Amplification was detected by FISH in 120 tumors (18.5%). RESULTS Alterations of Cep17 were observed in 177/647 cases (26.3%); in this subset the 56.2% of valuable tumors presented with nodal metastasis, HER-2 gene amplification was detected in 25/177 cases (14.1%). HER-2 protein overexpression was evaluated: 35 (20.1%) were scored 3+, 108 (62.1%) 2+ and 31 (17.8%) as 0/1+. None of HER-2 negative cases was amplified whereas 17 cases (9.8%) overexpressed/not amplified were found. The overall agreement was 74.2% (49/66 valuable cases). In 470 eusomic cases HER-2 gene amplification was detected in 95 cases (20.2%). The overall agreement in 434 eusomic cases valuable for HER2-expression and FISH was 96.8%. CONCLUSIONS HER-2 amplification showed a higher incidence in the cases without Cep17 copy number alterations, confirming that HER-2 gene alteration is not necessarily due to Chr17 disorder. In this study, a high number of aneusomic cases resulted overexpressed but not amplified and related to a high proliferation index (p= 0.002), differently by eusomic cancer, This result suggests that the presence of centromere 17 alterations could be associated to non-responsiveness to therapy independently from HER-2 amplification status.


Mutation Research | 2005

BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy

Stefania Tommasi; Antonella Crapolicchio; Rosanna Lacalamita; Michele Bruno; Anthony P. Monaco; Stella Petroni; Francesco Schittulli; S. Longo; Maria Digennaro; Daniele Calistri; A. Mangia; Angelo Paradiso


International Journal of Molecular Medicine | 2008

RhoA protein expression in primary breast cancers and matched lymphocytes is associated with progression of the disease

Antonia Bellizzi; Anita Mangia; Annalisa Chiriatti; Stella Petroni; Michele Quaranta; Francesco Schittulli; Andrea Malfettone; Rosa Angela Cardone; Angelo Paradiso; Stephan J. Reshkin


Histology and Histopathology | 2009

BRCA1 expression and molecular alterations in familial breast cancer

Anita Mangia; Annalisa Chiriatti; Stefania Tommasi; Filippo Menolascina; Stella Petroni; Francesco Zito; Giovanni Simone; Francesco Schittulli; Angelo Paradiso

Collaboration


Dive into the Stella Petroni's collaboration.

Top Co-Authors

Avatar

Giovanni Simone

National Cancer Research Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. Paradiso

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Lucia Caldarola

National Cancer Research Institute

View shared research outputs
Top Co-Authors

Avatar

Francesco Schittulli

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Stefania Tommasi

Buck Institute for Research on Aging

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Annamaria Catino

Catholic University of the Sacred Heart

View shared research outputs
Researchain Logo
Decentralizing Knowledge